BridgeBio (BBIO) investor relations material

Business overview and recent performance

• Focused on genetic diseases, with a decade of innovation leading to a strong commercial and late-stage portfolio.

• Attruby, a next-gen TTR stabilizer, is ramping with $720M annualized U.S. sales and strong ex-U.S. uptake.

• Three late-stage products (BBP-418, encaleret, infigratinib) are approaching regulatory submissions and launches starting end of this year.

• Attruby has captured over 25% first-line market share, driven by strong efficacy and differentiation.

• Market research suggests 30–40% peak frontline share for Attruby, with potential upside as adoption grows.

Product differentiation and market strategy

• Attruby’s clinical data show rapid and significant benefits: 3 months to separation, 42% reduction in survival events, 50% reduction in hospitalizations.

• Differentiation is reinforced by real-world evidence and subpopulation data, with more publications expected.

• Consistent weekly patient adds and expanding treatment-naive market support continued growth.

• Confident in sustaining growth despite future generic competition, citing analogs in other therapeutic areas.

• Combination therapy trends (e.g., with Ionis) are expected to favor Attruby as the preferred stabilizer.

Pipeline and upcoming launches

• Encaleret NDA for ADH1 submitted in May, with no AdCom expected; launch planned soon after PDUFA, targeting 10,000–12,000 U.S. patients.

• About 2,000 ADH1 patients currently diagnosed; ongoing efforts to confirm and prepare for launch.

• Pricing for encaleret expected to align with rare disease benchmarks like Crysvita and Skyclarys.

• Phase III for encaleret in chronic hypoparathyroidism launching summer 2026, aiming for rapid enrollment and potential label expansion.

• BBP-418 for LGMD2I/R9 targets 2,000–3,000 U.S. patients, with strong efficacy data and pricing expected in the range of rare neuromuscular drugs.